Transplanted hypoimmune (HIP)-modified allogeneic CD19-targeted CAR T cells control CD19+ tumor cells in fully immunocompetent allogeneic humanized mice, evading both the adaptive and innate immune ...

Sana Biotechnology is restructuring and narrowing its focus for the second time in less than a year. With its stock in the doldrums, the cell engineering biotech is pulling back from its in vivo ...

Preclinical data with SC262, a HIP-modified CD22-directed allogeneic CAR T cell, further support completed IND submission Validation of novel and fully-human GPRC5D-specific CARs for the development ...

Sana Biotechnology isn't revealing exactly how many employees have been affected by its latest round of layoffs, only confirming that the CAR-T-focused company has sought further “operational ...

Phase 1 trial to investigate multiple B-cell mediated autoimmune diseases First healthy donor-derived allogeneic CAR T cell therapy to announce IND clearance Expect to disclose initial clinical data ...

SEATTLE, April 19, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced data from four ...

SEATTLE, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the publication in ...

Sana Biotechnology is a biotech company focused on developing engineered allogeneic cells for diseases with unmet clinical needs. Sana's most advanced product candidates leverage CRISPR technology to ...

Shares of Sana Biotechnology (NASDAQ:SANA) added ~30% Thursday after announcing peer-reviewed data on hypoimmune (HIP) anti-CD19 chimeric antigen receptor T cells, the basis of its cancer candidate ...